Summary:
The treatment of acute venous thromboembolism and prophylaxis of recurrent events with heparin/low molecular weight heparin followed by vitamin K antagonists is limited by several factors. Oral direct thrombin inhibitors (ODTIs) showed a better pharmacological activity and might be an alternative in the treatment of venous thromboembolism. The Thrombin Inhibition in Venous Thromboembolism (THRIVE) program performed some studies developing the ODTI ximelagatran for this indication, and it is presented in the overview. The aim of the THRIVE I study was the dose finding, and that of the THRIVE IV study the applicability in hemodynamic stabile pulmonary embolism. A prospective, randomized, double blind trial was performed to compare oral ximelagatran with enoxaparin/warfarin for a 6-month treatment of acute venous thrombosis (THRIVE II and V). A second double blind study compared ximelagatran with placebo over 18 months after a 6-month anticoagulant therapy of acute deep vein thrombosis. The efficacy and safety of treatment of patients with acute deep venous thrombosis who received 2 ∞ 36 mg ximelagatran was not inferior to that of patients who received a conventional anticoagulant for prophylaxis of recurrent events over 6 months. Ximelagatran 2 ∞ 24 mg significantly reduced recurrent thromboembolic events compared to placebo without increasing the risk for hemorrhage. A reversible symptomless increase of alanine aminotransferase occurs in 6% to 9.6% of patients between months 2 and 4. The results of the follow-up studies suggest that thromboembolic events may recur in patients with acute venous thromboembolism after termination of treatment with both vitamin K antagonists and ximelagatran. Key Words: Venous thrombosis-AnticoagulationThrombin inhibitor-Ximelagatran-Warfarin. thrombosis in the leg, thromboembolic relapses can occur within 24 months in up to 25% of the patients (10) (11) (12) .
The limitations on the therapy of venous thromboembolisms with low molecular weight heparins in daily subcutaneous administration are bleeding (hemorrhagic) complications and the rare but serious heparin-induced thrombocytopenia (2) . The limitations on oral anticoagulation relate to severe and fatal bleeding (hemorrhagic) complications, monitoring, and relapses after termination of the therapy (13) . Therefore new anticoagulants were developed, which are bioavailable orally, show a shorter activity duration than vitamin K antagonists, and are administered at a fixed dosage and without regular monitoring of blood coagulation. Synthetic direct thrombin inhibitors represent one of these classes of substances (14) .
THE DEVELOPMENT OF ORAL DIRECT THROMBIN INHIBITORS (ODTIs)
In anticoagulation with immediate inhibition of thrombin, a distinction is made between indirect and direct inhibitors. Indirect inhibitors require antithrombin or heparin cofactor II for binding and to potentiate the inhibition of thrombin. Direct inhibitors bind to thrombin without a cofactor. A significant difference in the action of the inhibitors lies in the fact that thrombin binds to fibrin clots during their formation, remaining active at the same time. Active thrombin is present within an arterial or venous thrombus. Because of its size and charge, the heparin-antithrombin complex has practically no access to thrombus-bound thrombin and inhibits only circulating thrombin (2) .
Direct inhibitors with a higher molecular weight, that is, hirudins, bind to the "active site" and to the "exosite 1" of thrombin, which is situated at the edge of the thrombin molecule. The exosite 1 is also the binding point for fibrinogen, and so hirudins block fibrin-bound thrombin to only a small extent.
Up to now, coumarins have been available for oral anticoagulation. These substances inhibit the regeneration of vitamin K and thus the synthesis of the vitamin K-dependent clotting factors II (prothrombin), VII, IX, and X. Depending on the half-life time of these factors in the plasma, this leads to depletion of the precursor stages and, after falling below a critical level, to insufficient synthesis of active clotting factors. In addition, coumarins also inhibit the synthesis of the anticoagulatory proteins C and S, which also depend on vitamin K. They have a narrow therapeutic index and interact with several medicines and foodstuffs, and therefore require their coagulation-inhibiting effect to be monitored by means of the prothrombin time (9) .
New developments include synthetic smallmolecule thrombin inhibitors such as Argatroban, melagatran, and dabigatran, which bind only to the active site of thrombin. Ximelagatran and dabigatran represent the first thrombin inhibitors that are well absorbed orally ( Fig. 1) (5) . The ODTIs are hydrophilic prodrugs that are converted into the active form by hydrolases and esterases after oral ingestion. Melagatran is a synthetic dipeptide with lipophilic properties and a molecular weight of 429.5 daltons. The plasma levels lead to thrombin inhibition after 30 to 60 minutes (15) . Melagatran acts as a direct inhibitor of both free and fibrin-bound thrombin, and in addition it also inhibits thrombin formation (16) . It intensifies the fibrinolytic action of tissue plasminogen activator (t-PA) by inhibiting carboxypeptidase U and also inhibits the activity of thrombomodulin-bound thrombin (17) . The oral bioavailability of ximelagatran is about 20%. Maximum plasma levels are reached after 1.5 to 2 hours, and the half-life time is 3 to 4 hours. Excretion is mainly, that is, approximately 80%, renally in the unmetabolized state (15) .
This led to the development of a concept for the initial therapy and relapse prophylaxis of venous thromboembolisms by using the oral thrombin inhibitor ximelagatran, which is known as the THRIVE Program (THRombin Inhibition in VEnous thromboembolism). The basic facts proving the efficacy and tolerance (tolerability) of ximelagatran arise first from its rapid absorption, second from its constant oral bioavailability (15) , and third from its large therapeutic index (18) in preclinical trials. Therefore the clinical use of ximelagatran can be compared with heparins, low molecular weight heparins, and other parenterally administered thrombin inhibitors, and can also be compared with oral anticoagulants that produce hypocoagulability by inhibiting the vitamin K-dependent factors of the plasmatic clotting system.
Ximelagatran was tested clinically with regard to its efficacy and tolerance (tolerability) in different settings. First, it was compared to low molecular weight heparin (LMWH) and warfarin for the therapy of acute deep venous thrombosis in the leg. Second, it was compared to placebo for relapse prophylaxis after the termination of oral anticoagulation about 6 months after an initial venous thrombosis in the leg. Third, pharmacokinetic studies were performed in acute thromboembolisms. Last, a subgroup of patients, who were followed up after termination of treatment with ximelagatran, participated in the THRIVE Treatment and THRIVE III trials (6) .
THERAPY OF ACUTE DEEP VENOUS THROMBOSIS IN THE LEG WITH XIMELAGATRAN
The initial proof of the efficacy and tolerance of ximelagatran compared to dalteparin/warfarin comprised 160 patients (19) . Four dose levels of ximelagatran were allocated in a randomized manner: 2 × 24 mg, 2 × 36 mg, 2 × 48 mg, and 2 × 60 mg daily orally for 4 weeks. The comparison group received 2 × 100 IU of dalteparin daily subcutaneously and oral anticoagulation with warfarin from day 2. The anticoagulation with dalteparin was stopped as soon as the INR lay within the therapeutic range of >2.0 on two consecutive days. Ascending phlebography was performed on day 1 to confirm the diagnosis of deep venous thrombosis in the leg, and on day 28 to monitor the extent of the deep venous thrombosis in the leg (20) . The phlebographies were assessed based on the Marder score (21). The results show the change in the Marder score on day 1 compared to day 28 in the four treatment groups. The percentage fractional change in the Marder score in the individual therapy groups is plotted on the ordinates (Fig. 2) .
A change in the Marder score that was comparable with the dalteparin/warfarin therapy was recorded within 4 weeks with all the dose levels of ximelagatran. No serious bleeding complications occurred in any of the treatment groups. Clinical thromboembolism relapses were rare, at less than 2% in each treatment group, and insofar as can be assessed based on the small number of cases, equally frequent.
In a second clinical study (THRIVE I), the identical dosages of ximelagatran were compared with dalteparin/warfarin (22) . The primary target criterion was the change in the Marder score after 4 weeks of therapy. Fig. 3 shows the change in the Marder score of more than or less than 5 points at the end of the 28-day therapy compared to day 1. Thromboembolic complications, incidences of bleeding or therapy terminations for other reasons were the same in all the treatment groups. These results show a compa- rable efficacy of the oral thrombin inhibitor ximelagatran compared to dalteparin/warfarin on the Marder score in acute deep venous thrombosis of the leg. No differences regarding the dosages of ximelagatran on efficacy and tolerance are observable (22) .
To validate the efficacy and tolerance of ximelagatran, the dose level of 2 × 36 mg was selected from the studies mentioned above for comparison with 2 × 100 IU of enoxaparin with INRadjusted warfarin in a double-blind, randomized, and double-dummy design (with blinded INR values) (23). Two studies with an almost identical study design were started as the THRIVE II and THRIVE V studies. A joint assessment took place as the THRIVE Treatment study, which involved 2500 patients. The primary target criterion was the noninferiority of ximelagatran over 6 months compared to conventional therapy with enoxaparin/warfarin on the primary endpoint of objectively confirmed suspicion of thromboembolic relapses by means of compression sonography/phlebography or a lung scintigram/computed tomogram. The secondary endpoints were mortality and severe bleeding events.
Patients with the commencement of clinical symptoms of acute symptomatic deep venous thrombosis in the leg within the last 14 days and objective documentation by means of compression sonography received 2 × 36 mg of ximelagatran or 2 × 1 mg/kg body weight of enoxaparin and warfarin with a target INR of 2.0 to 3.0 for 6 months. Warfarin was started on day 2 and enoxaparin was stopped as soon as the INR was 2.0 or higher on 2 consecutive days. After the 6-month treatment there was a follow-up observation lasting 14 days (23).
A total of 1240 patients were treated with ximelagatran and 1249 with enoxaparin/warfarin; 26 thromboembolism relapses that could be documented objectively clinically (2.1%) occurred during therapy with ximelagatran; 24 (2.0%) thromboembolism relapses were observed under enoxaparin/warfarin. The absolute difference was 0.2%, with a confidence interval of -1.0 to +1.3%. Thus the primary target criterion of the noninferiority of ximelagatran compared to enoxaparin/warfarin was reached.
Severe bleeding complications occurred in the case of 25 patients (2.2%) receiving enoxaparin/warfarin and 14 (1.3%) of the patients receiving ximelagatran.
The mortality rate was 3.4% for those receiving the enoxaparin/warfarin therapy and 2.3% for those receiving ximelagatran. The results of the clinical endpoints are presented in Table 1 .
With regard to tolerance, the variation in alanine aminotransferase (ALAT) requires mention. With enoxaparin/warfarin the ALAT rose to more than 3 times normal in 2% of the patients, compared to 9.6% of the patients receiving ximelagatran. The ALAT increase was reversible in patients whose therapy was continued. Clinical symptoms of illness were not associated with the increase in the ALAT. The most frequent increases in the ALAT took place within the first 4 weeks of treatment with enoxaparin/warfarin, and between weeks 8 and 16 of treatment with ximelagatran.
During the follow-up period of 18 months, clinical symptoms of recurrent venous thromboembolism were objectively documented in 4 of 32 patients at month 12 twice, 15 and 17 following randomization to ximelagatran, and in 3 of 32 patients at month 10, 12, and 21, after randomization to enoxaparin/warfarin, respectively. No major bleeding complications occurred. One patient died in each treatment group at month 9 (enoxaparin/warfarin) and at month 24 (ximelagatran) due to a malignant disease (6) . 
ANTICOAGULATANT EFFECTS OF XIMELAGATRAN IN THROMBOEMBOLISM
The pharmacokinetic studies of ximelagatran at 2 × 48 mg daily by mouth were carried out during a 10-day therapy period in the case of 12 patients with hemodynamically stable pulmonary embolism (THRIVE IV). The clinical results show no thromboembolism relapses during the treatment period and no incidents of bleeding or other side effects (8) . The pharmacokinetic data (24) and the effects on aPTT are comparable to healthy persons in their results. They show that ximelagatran has an anticoagulatory effect lasting for at least 12 hours, and consequently a 2 × daily administration by mouth in the case of patients with acute thromboembolisms shows an antithrombotic effect. Ximelagatran does not accumulate. The anticoagulatory effect of melagatran is detectable by laboratory analysis using aPTT. However, aPTT is unsuitable for drug monitoring. On the other hand, the ecarin clotting time (ECT) can be used for this purpose.
In the context of other studies, the ecarin clotting time, which is a sensitive detector of the activity of direct thrombin inhibitors, was extended to twice as long 12 hours after an oral dose, and to 4.5 times as long 2 to 4 hours after the oral administration of 2 × 36 mg of ximelagatran (25). Thus the anticoagulant effects of ximelagatran can be checked by using the PTT and the ecarin time.
PROPHYLAXIS OF RECURRENT THROMBOEM-BOLIC EVENTS BY XIMELAGATRAN AFTER THE TERMINATION OF ORAL ANTICOAGULATION
The project aim of the THRIVE III study (26) was to reduce relapse thromboembolisms by therapy with ximelagatran compared to placebo after the termination of a 6-month course of oral anticoagulation following an initial acute deep venous thrombosis in the leg. A placebo-controlled study was possible because of the unproven need for relapse prophylaxis with oral anticoagulants extending beyond 6 months. The dose regimen was specified as 2 × 24 mg of ximelagatran daily by mouth and a therapy period of 18 months. The primary endpoint was the clinical suspicion of relapsing thromboembolic events confirmed by objective methods. Mortality together with severe and a combination of severe and minor bleeding complications were secondary endpoints. The ximelagatran group comprised 617 patients and the placebo group had 616 patients.
Thromboembolic relapses occurred under placebo in 71 of 611 patients (12.6%), of which 23 manifested solely as a pulmonary embolism. Under treatment with 2 × 24 mg of ximelagatran there were 12 thromboembolic relapses (2.8%), of which 2 occurred solely as a pulmonary embolism. The reduction in the thromboembolic events as a result of ximelagatran corresponds to 84% (hazard ratio 0.16; 95% confidence interval 0.09-0.30; P < 0.0001; Table 2 ).
Five severe bleeding complications occurred under placebo and 6 under ximelagatran. No fatal bleeding complications were observed. Based on the regular examination for slight bleeding complications including screening (urine, feces), there were 111 hemorrhages under placebo and 134 hemorrhages under ximelagatran (21.0% vs 23.9%; hazard ratio 1.19; 95% confidence interval 0.93-1.53; P = 0.1703). Seven patients died during treatment with placebo and 6 during treatment with ximelagatran (see Table 2 ). Based on clinical suspicion of objectively documented thromboembolic relapses, mortality, and severe bleeding complications over 6 months during therapy of the venous thrombosis with ximelagatran or enoxaparin/warfarin. CI = confidence interval, ITT = intention to treat, OT = on treatment.
An increase in the ALAT to more than three times the upper reference range occurred in 1.2% of the patients receiving placebo and 6.4% of the patients receiving ximelagatran. Symptoms of illness specific to the liver did not occur in any of the patients. The increase in the ALAT was reversible during continuation of the therapy. No other side effects occurred.
During the follow-up period of a small subgroup of patients, 3 of 9 patients developed recurrent venous thromboembolism at month 19, 21, and 32, and no patient initially randomized to ximelagatran and placebo, respectively. In addition, 1 patient each suffered from a retinal vein thrombosis at month 12 (ximelagatran), an arterial thrombosis at month 3 (placebo), and a major intramuscular bleeding complication at month 12 (placebo). No patient died during the study period. At the end of 18 months of follow-up, the incidences for recurrent venous thromboembolism did not differ between the groups (6).
DISCUSSION
The acute therapy of deep venous thrombosis with or without pulmonary embolism in the acute treatment and in relapse prophylaxis with 2 × 36 mg of ximelagatran is not inferior to conventional treatment with body weight-adjusted subcutaneous low molecular weight heparin and relapse prophylaxis with warfarin at an INR between 2.0 and 3.0.
After the cessation of the conventional therapy of thromboembolic events beyond 6 months, prolonged relapse prophylaxis for a further 18 months with 2 × 24 mg of ximelagatran compared to placebo leads to an 84% reduction in clinically symptomatic thromboembolic relapses. With effective anticoagulation, no increase in severe or minor bleeding complications is found for more than 18 months. A comparison between these results and those from the literature yields the following relationships:
With oral anticoagulation using warfarin over 6 months and at an INR of 2 to 3, the relapse rate of thromboembolisms is 1.45% per year (12) . With anticoagulation over 4 years at an INR of 1.5 to 1.9, 2.5% of thromboembolic relapses occurred per year, and 6.5% per year with placebo (27,28). A comparison of the anticoagulation intensities over 4 years reveals thromboembolic relapses of 0.5% per year at an INR of 2.0 to 3.0, and 1.55% per year at an INR of 1.5 to 1.9 (27). The more recent results have lower thromboembolism relapse rates, which are possibly related to a better quality of INR monitoring.
The increase in the alanine aminotransferase during therapy with ximelagatran occurred between the 2nd and the 4th month and is also reversible during the continuation of the therapy. It is not associated with any clinical symptoms of illness. The variation with time is different when compared to heparins and vitamin K antagonists. Causes related to ethnicity, genetics, or metabolism are being analyzed to enable risk groups to be identified.
There are no restrictions and problems as a result of medication interactions, a variation in the anticoagulant effect due to changes in dietary Based on clinical suspicion of objectively documented thromboembolic relapses, mortality, severe bleeding complications, and severe/minor bleeding complications during prolonged relapse prophylaxis after thromboembolism, using ximelagatran or placebo, after an initial thrombosis therapy lasting 6 months had been carried out. CI = confidence interval, OT = on treatment.
habits, or elaborate management before and after surgical procedures as in the case of therapy with vitamin K antagonists. Patient compliance is relevant because of the short half-life time of ximelagatran. Ximelagatran is excreted renally. Therefore an analysis of the coagulationinhibiting effect of ximelagatran might become significant in the future, both in the context of compliance and in the event of changes in kidney function. According to preliminary results, the aPTT and the ecarin clotting time are suitable for this purpose. However, it is not possible at the present time to state subtherapeutic or therapeutic ranges for the coagulation-inhibiting effects of ximelagatran either. The follow-up of a subgroup of patients of the THRIVE treatment and THRIVE III studies suggest that recurrent thromboembolic events may occur in patients not only after termination of treatment with warfarin but also with ximelagatran (6) .
In summary, the results show that the initial therapy of acute venous thrombosis in the leg with 2 × 36 mg of ximelagatran is not inferior to the conventional treatment using low molecular weight heparin and relapse prophylaxis over 6 months with vitamin K antagonists. Extended relapse prophylaxis with 2 × 24 mg of ximelagatran over or beyond 18 months reduces the clinical thromboembolism relapses compared to placebo without an increase in bleeding complications. 
